24-01-2022 07:30 via finanzen.net

MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study

Regulatory News:MaaT Pharma (EURONEXT: MAAT - the "Company"), a French clinical-stage...